Farnesyltransferase inhibitor BMS-214662 induces apoptosis in

myeloma cells through PUMA upregulation, Bax and Bak activation and

Mcl-1 elimination

María Gómez-Benito, Isabel Marzo, Alberto Anel and Javier Naval

Departamento de Bioquimica y Biologia Molecular y Celular, Facultad de Ciencias,

Universidad de Zaragoza, Spain.

Running Title: BMS-214662-induced apoptosis in myeloma cells

Corresponding author:

Dr. Isabel Marzo

Departamento de Bioquimica y Biologia Molecular y Celular

Facultad de Ciencias, Universidad de Zaragoza; 50009 Zaragoza (Spain)

Fax: (34) 976 762 123; e. mail: imarzo@unizar.es

Abbreviations: FTI, Farnesyl transferase inhibitor; AIF, Apoptosis-Inducing Factor; $\Delta\Psi_m$,

mitochondrial transmembrane potential; $DiOC_6(3)$, 3,3'-dihexyloxacarbocyanine iodide.

Number of text pages: 17

Tables: 0

Figures: 7

References: 43

Words in Abstract: 244

Introduction: 340

Discussion: 1059

ABSTRACT

We have studied the mechanism of apoptosis elicited by the farnesyltransferase inhibitor BMS-214662 in human myeloma cell lines. Low concentrations of BMS-214662 efficiently inhibited protein farnesylation but did not affect to the activation of Akt. BMS-214662 treatment increased levels of the BH3-only protein PUMA, induced proapoptotic conformational changes of Bax and Bak, reduction of Mcl-1 levels, $\Delta\Psi_m$ loss, cytochrome c release, caspase activation, AIF nuclear translocation, phosphatidylserine exposure and development of apoptotic morphology. Western blot analysis of cell extracts revealed the activation of caspases 2, 3, 8 and 9 upon treatment with BMS-214662. The general caspase inhibitor Z-VAD-fmk significantly prevented BMS-214662-induced death in U266 and RPMI 8226 cells but not in NCI-H929 cells. A mixture of selective caspase inhibitors for caspases 9 (Z-LEHD-fmk), 3 (Z-DEVD-fmk) and 6 (Z-VEID-fmk) approached the protective effect of Z-VAD on cell death. However, Z-VAD-fmk did not prevent BMS-214662-induced Bax and Bak activation and decrease of Mcl-1 levels. According to its effect on cell death, Z-VAD-fmk inhibited nuclear translocation of AIF in RPMI 8226 and U266 but not in NCI-H929 cells. These results suggest that apoptosis triggered by BMS-214662 is initiated by a PUMA/Bax/Bak/Mcl-1-dependent mechanism. In some cell lines, Bax/Bak activation is not sufficient *per se* to induce mitochondrial failure and release of apoptogenic proteins and so caspases need to be activated to facilitate apoptosis. After $\Delta\Psi_m$ loss, execution of apoptosis was performed in all cases by a cytochrome c-enabled, caspase-9 triggered, caspase cascade and the nuclear action of AIF.

INTRODUCTION

Farnesyltransferase is a cytosolic enzyme that catalyses the transfer of the 15-carbon isoprenoid chain from the farnesyl pyrophosphate to the Cys residue of a conserved CAAX sequence at the carboxyl terminus of proteins. This allows protein association to cell membranes *via* the farnesyl group. Substrates of farnesyltransferase include Ras (Haluska,2002), which critically control proliferative signals in normal and malignant cells, RhoB, a small G-protein involved in control of actin cytoskeleton and endocytosis (Du,1999), the cytosolic chaperone HDJ-2 (Adjei,2001), peroxysomal protein PxF and lamins A and B (Haluska,2002). Since Ras proteins require farnesylation to localize at the plasma membrane and become biologically active, a number of farnesyltransferase inhibitors (FTIs) have been developed as potential cancer therapeutics (Sebti and Hamilton,2000). In addition to Ras, current evidence suggests that the anticancer activity of the FTIs may be due to blocking of function of other farnesylated proteins (Haluska,2002). A suitable candidate for therapy with FTIs is multiple myeloma. Myeloma is the second most frequent hematological malignancy, with a median survival inferior to 4 years (San Miguel,1999). Gain-of-function mutations of Ras are found in up to 50% of myeloma cases and their frequency increases as disease progresses (Reuter,2000). Ras is critically implicated in proliferation, through the activation of Raf/Mek/ERK kinase pathway, and survival, *via* PI3-kinase/Akt pathway (Hu,2003, Mitsiades,2002, Ogata,1997) of myeloma cells. BMS-214662 is a non-thiol, non-peptide inhibitor of Farnesyl transferases (Singh and Lingham,2002). Preclinical studies have shown that some types of human leukaemia cell lines are sensitive to growth inhibition by BMS-214662 (Rose,2001). In addition, results from a phase I trial indicate that BMS-214662 may be useful for the treatment of human acute leukemias and myelodysplasias (Kurzrock,2002). Here we show that low concentrations of BMS-214662 efficiently inhibit

protein farnesylation and induce apoptosis in human myeloma cell lines. Apoptosis is

associated in most cases with an increase in PUMA levels, conformational changes of

Bax and Bak, elimination of Mcl-1, caspase activation and AIF translocation to cell

nucleus. These results provide a molecular framework for the possible utilization of BMS-

214662 in the therapy of multiple myeloma.

EXPERIMENTAL

Materials

BMS-214662, an imidazole-containing tetrahydrobenzodiazepine (Rose,2001) was kindly provided by Bristol-Myers Squibb (Princeton, New Jersey). Cycloheximide and MTT were from Sigma (Madrid, Spain). Peptide caspase inhibitor Z-VAD-fmk was from Bachem.(Switzerland), Z-DEVD-fmk, Z-LEHD-fmk, Z-IETD-fmk and Z-VEID-fmk were from BDPharmingen (Madrid, Spain) and Z-VDVAD-fmk from Calbiochem (Madrid, Spain).

Cell proliferation and toxicity assays

Human myeloma cell lines RPMI 8226, NCI-H929, U266 (clone B1) and the B-leukemia IM-9, obtained from the peripheral blood of a patient with myeloma, were from the ATCC. All cell lines were routinely cultured at 37°C in RPMI 1640 medium supplemented with 10% fetal calf serum, L-glutamine and penicillin/streptomycin (hereafter, complete medium), using standard cell culture procedures. In proliferation assays, cells (3-5×10^5 cells/ml) were treated in flat-bottom, 24-well (1 ml/well) or 96-well plates (100 µl/well) with different concentrations of BMS-214662 (0.075–1 µM) in complete medium for different times, as indicated. For apoptosis inhibition assays, cells were preincubated, with either one or mixtures of the following inhibitors: 100 µM Ac-DEVD-fmk, 100 µM Z-LEHD-fmk, 100 µM Z-IETD-fmk, 100 µM Z-VEID-fmk, 200 µM Z-VDVAD-fmk or 100 µM Z-VAD-fmk for 1 h, prior to the addition of BMS-214662. The dependence of apoptosis on *de novo* protein synthesis was evaluated by adding cycloheximide (0.5 µg/ml) to cultures 1 h before BMS-214662 treatment. Cell proliferation was determined by a modification of the MTT-reduction method (Alley,1988) and viability by microscopical inspection of Trypan

blue stained cells. Cells exhibiting a blebbing morphology, defined by the appearance of distinct protrusions of the plasma membrane and/or vacuolization, were also scored as non-viable. Nuclear alterations during apoptosis were analyzed by labeling with *p*-phenylenediamine (PPDA) in oxidized glycerol and visualized by fluorescence microscopy (Gamen,1998).

Flow cytometry analysis

Phosphatidylserine exposure and mitochondrial membrane potential ($\Delta\Psi_m$) were simultaneously evaluated in the same cells. Briefly, cells (2.5×10^5 in 200 µl) were incubated with 2 nM $DiOC_6(3)$ (Molecular Probes) at 37°C for 10 min in binding buffer (140 mM NaCl, 2.5 mM $CaCl_2$, 10 mM Hepes/NaOH, pH 7.4). Then, 0.5 µg/ml annexin V-PE (Caltag) were added and incubated at room temperature for 15 min. Cell suspension was diluted to 1 ml with binding buffer and analyzed in a flow cytometer (Epics XL-MCL, Beckman/Coulter). Conformational changes of Bax and Bak proteins were assessed by intracellular immunostaining using specific antibodies recognizing only the proapoptotic conformation of these proteins (Griffiths,1999, Panaretakis,2002, Yamaguchi,2002). Cells (1×10^6) were cultured in complete medium (controls) or medium containing BMS-214662 for 20 h in the absence or in the presence of Z-VAD-fmk. Then, cells were fixed with 0.5% paraformaldehyde in PBS (15 min, 4ºC) and incubated for 25 min at room temperature with 0.5 µg of anti-Bax (6A7, BDPharmingen), anti-Bak (TC100, Oncogene) or an irrelevant mouse IgG in 100µl of PBS containing 0.1% saponin and 5% goat serum. Cells were washed with 0.03% saponin in PBS, incubated with a FITC-labeled anti-mouse IgG antibody (Caltag) and analyzed by flow cytometry. Quantitative analysis of cytochrome *c* release from mitochondria during apoptosis was assayed by the method of Waterhouse & Trapani (Waterhouse and Trapani,2003). In brief, cells (1×10^6) were

cultured in complete medium alone (controls) or medium containing BMS-214662 in the absence or presence of Z-VAD-fmk. Cells were permeabilized with 100 µl digitonin (50 µg/ml in PBS containing 100 mM KCl) for 5 min on ice, fixed in 4% paraformaldehyde in PBS for 20 min at room temperature and resuspended in blocking buffer (3% BSA, 0.05% saponin in PBS). Cells were incubated overnight at 4ºC with a 1/200 dilution of anti-cytochrome c antibody (6H2.B4, BDPharmingen) in blocking buffer, washed and incubated with a FITC-labeled anti-mouse IgG antibody. Finally, cells were resuspended in PBS and analyzed by flow cytometry (Epics XL-MCL, Coulter). For cell cycle analysis, cells (1×10^6) were washed with PBS pH 7.4, containing 1 mg/ ml glucose, and fixed with 70% ethanol at -20ºC for 24 h. Cells were next incubated for 1 h at room temperature in PBS containing 0.5 mg/ml RNase and 20 µg/ml propidium iodide and analyzed by flow cytometry.

Immunofluorescence analysis

AIF translocation from mitochondria to nucleus was analyzed by confocal microscopy. Cells (1.5×10^6) were cultured in complete medium containing or not BMS-214662, fixed in 4% paraformaldehyde for 15 min and centrifuged onto poly-L-lysine-coated coverglasses. Coverglasses were washed in PBS, briefly immersed in 0.1% saponin in PBS, placed onto a drop of a 1/200 dilution of a rabbit anti-AIF antiserum (kindly provided by Drs. Santos Susin and Guido Kroemer, CNRS, France) and incubated at room temperature in a humidified chamber for 30 min. Coverglasses were washed twice with 0.1% saponin and incubated a FITC-labeled anti-rabbit IgG antibody. Finally, coverglasses were sequentially washed with 0.1% saponin, PBS and distilled water and mounted onto glass slides over a drop of Mowiol (Calbiochem). Preparations were

observed in a Zeiss 310 confocal microscope, and analyzed using the LSM 3.95 software.

Subcellular fractionation and Western blot analysis

Akt activation, HDJ-2 farnesylation, caspase activation and levels of Bcl-2 superfamily proteins were analyzed by Western blot essentially as described previously (Perez-Galan,2002). For the detection of the active, phosphorylated form of Akt, myeloma cells ($1x10^6$ cells/ml) were incubated for 1h with 200 IU/ml IL-6 in the presence or absence of BMS-214662. Cells were lysed in 50 mM Tris/HCl pH 7.4 buffer containing 0.15 mM NaCl, 10% glycerol, 1mM Na_3VO_4, 10mM $Na_4P_2O_7$, 50 mM NaF, 1 mM EDTA, 10 µg/ml leupeptin, 1mM PMSF and 1% Triton X-100. Solubilized proteins from equal numbers of Trypan-blue negative cells ($1x10^6$/lane) were resolved by SDS-12%PAGE, transferred to nitrocellulose membranes and incubated with primary antibodies diluted in TBS-T (10 mM Tris/HCl pH 8.0, 0.12 M NaCl, 0.1% Tween-20, 0.05% sodium azide), containing 5% skimmed milk, as described previously (Gamen,1997). Primary antibodies anti human proteins used were: anti COX-I (1D6, Molecular Probes); anti HDJ-2 (KA2A5.6, Neomarkers); anti phospho-Akt (Ser473, 9271, Cell Signalling); anti caspase-8 (5F7) and anti-Bak (06-536) from UBI; anti caspase-3 (clone 19), anti caspase-9 (68086E), anti active caspase-3 (557035), anti Bax (554104), anti-cytochrome c (7H8-2C12) and anti-p53 (DO-1) all from BDPharmingen; anti Bim (22-40, Calbiochem); anti caspase-2 (sc-625), anti Bcl-2 (sc-783), anti Bcl-x$_L$ (sc-1041), anti Mcl-1 (sc-819) and anti Bik (sc-1710), all from Santa Cruz Biotechnology and anti PUMA (ab9643) from AbCam. Membranes were washed with TBS-T and incubated with 0.2 µg/ml of the corresponding phosphatase alkaline-labeled secondary antibody (Sigma). Western blots were revealed with the BCIP/NBT substrate, as described (Gamen,1997). Control of protein loading was

achieved by reprobing with anti β̃actin or anti α-tubulin (Sigma). Western blots were

sequentially analyzed for several proteins by a modification of the multiple blotting assay

method (Krajewski,1996), as described (Perez-Galan,2002). Release of cytochrome *c*

from mitochondria was determined by subcellular fractionation of digitonin-treated cells

as described by (Piqué,2000) and Western blot analysis. Purity of fractions was

assessed by analysing the presence of the inner mitochondrial membrane protein COX-I

and cytosolic tubulin in the same blots.

RESULTS

BMS-214662 inhibits farnesylation and induces apoptosis in myeloma cells

Treatment with BMS-214662 caused cell death in a dose-dependent way (Fig. 1A) in all cell lines tested, though their relative sensitivity varied. Analysis of cell proliferation by the MTT-assay, indicated that IC_{50} increased in the order: NCI-H929 (50 nM) < RPMI 8226 ≈ IM-9 (0.2 μM) < U266 (0.8 μM) after a 24 h incubation. To assess the inhibition of farnesyltransferase activity in cells, farnesylation of cytosolic chaperone HDJ-2 and lamin A, recognized as suitable markers (Adjei,2001), was analyzed by Western blot. BMS-214662, at apoptosis-inducing doses, significantly inhibited farnesylation of HDJ-2 (Fig. 1B) in all cell lines and lamin A in cells expressing this protein (RPMI 8226, NCI-H929 and IM-9, data not shown). The appearance of a lower mobility band corresponding to the nonfarnesylated HDJ-2 is probably due to blockade of post-farnesylation proteolytic processing (Adjei,2001, Karp,2001). On the other hand, treatment with BMS-214662 had no effect on the levels of activated Akt (data not shown), ruling out the possibility that apoptosis was due to Akt inhibition. Moreover, BMS-214662 did not modify the levels of activated MAP kinases JNK, p38 and ERK (data not shown). Morphological evaluation revealed that cells treated with BMS-214662 exhibited typical features of apoptosis such as cell shrinking, chromatin condensation and, except for NCI-H929 cells, nuclear fragmentation and formation of apoptotic bodies (Fig 1C).

BMS-214662 causes caspase activation, $\Delta\Psi_m$ loss and phosphatidylserine exposure

Caspase activation during BMS-214662 induced-apoptosis of RPMI 8226, U266, NCI-H929 and IM-9 cells was analyzed by Western blotting. In all cell lines, BMS-214662 induced a significant activation of caspase-9 (Fig. 2A) and caspase-3 (Fig. 2B), as shown

by reduction in the intensity proenzymes and, in the case of caspase-3, by the appearance of the 17 kDa-band of the active subunit (Fig. 2B). RPMI 8226 cells expressed low levels of caspase-3 (Fig. 2B). Caspase-8 and caspase-2 were also activated upon BMS-214662 treatment in all cell lines (Fig. 2C,D).

Treatment of myeloma cells with BMS-214662 caused phosphatidylserine exposure and loss of $\Delta\Psi_m$ (Fig 3A). Cotreatment with Z-VAD-fmk did not prevent $\Delta\Psi_m$ loss, although attenuated phosphatidylserine translocation NCI-H929 cells (Fig. 3). However, in RPMI 8226 and U266 cells Z-VAD-fmk completely prevented $\Delta\Psi_m$ loss and PHOSPHATIDYLSERINE exposure induced by BMS-214662 at 24h (Fig. 3). Inhibition by Z-VAD-fmk of $\Delta\Psi_m$ loss caused by BMS-214662 in IM-9 cells was not complete (Fig 3). A significant proportion of cells showed an intermediate $\Delta\Psi_m$ ($\Delta\Psi_m^{int}$) when compared to untreated cells ($\Delta\Psi_m^{high}$) and cells treated with BMS-214662 alone ($\Delta\Psi_m^{low}$) (Fig 3). Cotreatment of cells with Z-VAD-fmk also prevented development of apoptotic morphology, although peripheral chromatin condensation, characteristic of AIF action (see later) was still noted in NCI-H929 and IM-9 cells (Fig. 1C). We also analyzed the effect of selective caspase inhibitors on BMS-214662-induced apoptosis in cell lines where the protective effect of Z-VAD was the greatest (RPMI 8226 and U266). Z-DEVD-fmk (inhibitor of caspases 3, 7 and 8), Z-VDVAD-fmk (minimal inhibitor of caspase-2), Z-IETD-fmk (caspases 8 and 10) and Z-LEHD-fmk (caspase-9) failed to prevent BMS-214662-induced $\Delta\Psi_m$ loss in U266, RPMI 8226 and NCI-H929 cells, although phosphatidylserine exposure was prevented in part (data not shown). Nuclear condensation and fragmentation was inhibited in U266, RPMI 8226, NCI-H929 and IM-9 cells treated with BMS-214662 in the presence of Z-DEVD-fmk, but a high percentage of cells exhibited peripheral chromatin condensation (data not shown), reminiscent of AIF action. Most (85-90%) of the protective effect of Z-VAD-fmk in RPMI 8226 and U266 cells

could be mimicked by the addition of a mixture of inhibitors for caspases 9, 3 and 6 (Z-LEHD-fmk + Z-DEVD-fmk+ Z-VEID-fmk, 100 μM each) (Fig 3). Any combination of two of these inhibitors, as well as the combination of Z-LEHD-fmk + Z-VDVAD-fmk did not prevent cell death (data not shown). In other experiments, cells were incubated for longer periods with BMS-214662 in the continuous presence of Z-VAD-fmk and cell death was evaluated by annexin V-labeling. Caspase inhibition by Z-VAD-fmk did not affect the toxicity in NCI-H929 cells at any time but preserved viability of RPMI 8226 and U266 cells for at least 48 h and 36 h (data not shown). Protein synthesis inhibition with cycloheximide did not prevent BMS-214662 toxicity in myeloma cells (data not shown). In NCI-H929 cells, cycloheximide potentiated the toxicity of BMS-214662. Treatment of NCI-H929 cells with cycloheximide alone caused a reduction in Mcl-1 levels (data not shown) without significant toxicity, suggesting that this could be the mechanism of potentiation of BMS-214662 toxicity in these cells.

Effect of BMS-214662 on Bcl-2 superfamily proteins

Western Blot analysis revealed that BMS-214662 treatment did not significantly affect to the levels of Bax, Bak and Bcl-2 (Fig. 4A) in any of the cell lines. However, treatment with BMS-214662 induced pro-apoptotic conformational changes in Bax and Bak, as determined by flow cytometry (Fig. 5). These conformational changes have been previously observed in other apoptotic models (Griffiths,2001, Griffiths,1999). However, Bak protein did not undergo the conformational change in RPMI 8226 cells treated with BMS-214662 (Fig. 5). Other drugs that induce apoptosis in RPMI 8226, such as doxorubicin and daunorubicin, were also unable to induce the conformational change of Bak (data not shown). Inhibition of caspases with Z-VAD-fmk did not prevent conformational changes of Bax and Bak in U266, NCI-H929 and RPMI 8226 cells (Fig. 5).

A significant reduction in Mcl-1 levels was observed in RPMI 8226 and U266 cells after

treatment with BMS-214662 (Fig. 4A) that was not prevented by Z-VAD-fmk (Fig. 4C).

Levels of Bcl-x$_L$ and of Bcl-x$_S$ also diminished to a lesser extent in U266, RPMI 8226 and

IM9 cells (Fig 4A). The BH3-only proteins Bim, Bik and Bad were expressed by U266 and

NCI-H929 cells, but not by RPMI 8226 and IM-9 cells. Levels of these proteins did not

significantly change after treatment with BMS-214662 (Fig. 4A) in U266 cells and only Bad

levels were reduced in NCI-H929 cells. The BH3-only protein PUMA was expressed by all

cell lines and their α and β isoforms were detected by Western Blot (Fig. 4B). PUMA

expression significantly increased in RPMI 8226 and NCI-H929 cells, but no in U266 cells

after 6 h of treatment with BMS-214662 (Fig. 4B). This increase of PUMA levels was

concomitant in RPMI 8226 and NCI-H929 cells with an increase in levels of p53 protein

(Fig 4B). Congruently, BMS-214662 induced cell cycle arrest at G$_1$ in NCI-H929, but not in

U266 cells (data not shown). At longer incubation times, BMS-214662 produced a marked

decrease of PUMA levels in all cell lines, independently of caspase activation (Figure 4).

BMS-214662 causes release of cytochrome c and AIF from mitochondria

Mitochondrial release of cytocrome c from myeloma cells was determined by flow

cytometry (Fig. 6) and also by subcellular fractionation and Western blot analysis (not

shown), with equivalent results. BMS-214662 treatment induced the release to cytosol of

cytochrome c in U266, RPMI 8226 and NCI-H929 cells (Fig. 6), though at different extent.

Cotreatment with the general caspase inhibitor Z-VAD-fmk, prevented most of the

cytochrome c release in U266 and RPMI 8226 cells but not in NCI-H929 cells (Fig 6),

according to the observed inhibitory effect of Z-VAD-fmk on $\Delta\Psi_m$ loss, phosphatidylserine

exposure and cell death in U266 and RPMI 8226, but not in NCI-H929 cells (Fig. 3).

BMS-214662 treatment also induced AIF translocation from mitochondria to nucleus in

RPMI 8226, U266 and NCI-H929 cells, as observed by immunofluorescence microscopy (Fig. 7). In untreated cells, AIF was only localized in cytoplasm, with a punctuate pattern congruent with its mitochondrial location. After treatment with BMS-214662, AIF staining became diffuse and localized in cytoplasm and nucleus. Nuclear translocation of AIF in U266 and RPMI 8226 cells, but not in NCI-H929 cells, was blocked by caspase inhibition with Z-VAD-fmk (Fig. 7). Treatment with the caspase-3 inhibitor Z-DEVD-fmk (100 μM) did not prevent AIF nuclear translocation in any cell line (not shown).

DISCUSSION

Farnesyltransferase inhibitors (FTIs) were developed as potential cancer therapeutics, initially designed to target oncogenic Ras (Adjei,2001). In sensitive cells, most FTIs tested cause cell growth inhibition favoring death by neglect but not directly inducing apoptosis (Bolick,2003, Du,1999, Le Gouill,2002). In some myeloma cell lines, FTIs like R115777 and perillic acid induce apoptosis (Beaupre,2004, Beaupre,2003). Here, we show that BMS-214662 efficiently induces apoptosis in myeloma cells at much lower doses than those reported for other FTIs (Bolick,2003, Le Gouill,2002). As shown, treatment with BMS-214662 blocked protein farnesylation, inhibited cell growth and induced apoptosis in cell lines that express either mutated (RPMI 8226, NCI-H929) or wild-type Ras (U266) (Bolick,2003). These results agree with previous reports showing that the presence of mutated Ras is not essential for the action of FTIs (Du,1999). In fact, at least some FTIs acts also on alternative molecular targets. For instance, SCH66336, which is under clinical testing, efficiently inhibits NF-κB (Takada,2004) and Akt activation (Chun,2003) in tumor cells. Our present results indicate that BMS-214662 did not alter the levels of activated Akt under basal conditions or upon stimulation with IL-6. Anyway, our results indicate that at farnesylation inhibitory doses, BMS-214662 causes apoptosis in myeloma cells through the engagement of the mitochondrial pathway. The relative role of caspases and Bcl-2 superfamily proteins in the induction phase of apoptosis depends on the myeloma cell line. BMS-214662-induced apoptosis is caspase-dependent in U266 and RPMI 8266 cells, but not in NCI-H929 cells. Moreover, Z-VAD-fmk block most, but not all, of the release of cytochrome c and AIF induced by BMS-214662 in RPMI 8226 and U266 cells. These results agree with a previous report showing that cytochrome c release may occur in two steps, being the first caspase-independent and the second promoted by a caspase-amplification loop(Chen,2000).

Therefore, it is reasonable to speculate that the differences observed in myeloma cell lines are due to the relative efficiency of proapoptotic multidomain proteins to cause the release of cytocrome *c* and AIF from mitochondria.

NCI-H929 cells express the BH3-only proteins Bad, Bik and, at higher levels, Bim and PUMA. Treatment with BMS-214662 increases the levels of p53 and its regulated protein PUMA. PUMA, Bim, Bad and Bik can bind to and neutralize Mcl-1, Bcl-2 and Bcl-x$_L$ and thus facilitate the conformational change of Bax and Bak. This change is necessary and sufficient to provoke the release of cytochrome *c*, which seems to be the main responsible for $\Delta\Psi_m$ loss, and of AIF. AIF causes caspase-independent cell death and so caspase inhibition by Z-VAD-fmk only affects to the morphology of dying cells but not to the extent of cell death. U266 cells express only mutant p53 and RPMI 8226 cells express both wild type and mutant p53 proteins (Liu,2003, Teoh,2000). Accordingly, after BMS-214662 treatment, levels of p53 and PUMA remained constant in U266 cells and increased in RPMI 8226 cells. However, RPMI 8226 cells do not express the BH3-only proteins Bim, Bad and Bik, and Bak does not acquire the proapoptotic conformation upon treatment with BMS-214662 or other drugs (data not shown). In RPMI 8226 cells, the action of PUMA would only enable the release of limited amounts of cytocrome c, being dependent of active caspases to cause $\Delta\Psi_m$ loss and the release of AIF and further amounts of cytochrome *c*. These results could explain why Z-VAD-fmk completely blocks cell death for nearly two days in U266 and RPMI 8226 but not in NCI-H929 cells. On the other hand, only the combination of inhibitors of caspases 9, 3 and 6, but not others, offered a degree of protection approaching that of Z-VAD-fmk in RPMI 8226 and U266 cells. This agrees with the canonical model of apoptosis execution with caspase-9 as the apical caspase, and the improved protection offered by Z-VAD-fmk versus Z-LEHD-fmk is probably due to its better accessibility to cellular caspase-9 (Scoltock and

Cidlowski,2004). Also, a possible role of Bid can be ruled out since Bid requires its previous proteolytic activation by caspase-8 (Gross,1999) and inhibition of this caspase with Z-IETD-fmk did not prevent cell death. Protection by Z-VAD in these cell lines is not permanent and 48 h after the initiation of treatment cells began to die in the absence of caspase activation. BMS-214662 also induced a marked decrease in the levels of Mcl-1, a short-lived protein critical for myeloma survival (Derenne,2002, Jourdan,2003, Zhang,2002) and downregulation of Mcl-1 occurs during apoptosis of myeloma cells (Gomez-Bougie,2004, Pei,2003, van de Donk,2003). Apoptosis triggered by BMS-214662 was associated with reduction of Mcl-1 protein expression in all cell lines analyzed. Moreover, treatment of H929 cells with cycloheximide decreased the levels of Mcl-1 and increased their sensitivity to BMS-214662. A similar phenomenon of acceleration of apoptosis after cycloheximide-induced Mcl-1 downregulation has been described in endothelial (Bannerman,2001) and HeLa cells (Nijhawan,2003). Downregulation of Mcl-1 could result from both protein synthesis blockade and degradation of existing Mcl-1 by the proteasome (Nijhawan,2003). Moreover, preliminary ongoing experiments from our laboratory indicates that overexpression of Mcl-1 in myeloma cell lines protects them from BMS-214662-induced apoptosis (data not shown). All these data support a key role for Mcl-1 in the susceptibility to apoptosis of myeloma cell lines.

In summary, BMS-214662 inhibits farnesylation and induces an increase in PUMA levels, conformational changes of Bax/Bak and Mcl-1 elimination in myeloma cells. This facilitates the release of cytochrome c and AIF from mitochondria and cause loss of $\Delta\Psi_m$, caspase activation and nuclear translocation of AIF. The combined action of AIF and caspases leads to the apoptotic phenotype. In some cell lines like RPMI 8226 and U266, activation of proapoptotic Bcl-2 family proteins is not sufficient *per se* to cause

mitochondrial destabilization. In these cases, after the induction of Bax/Bak conformational change, caspases activated downstream of mitochondria are needed to cause rapid loss of $\Delta\Psi_m$ and the complete release of cytochrome c and AIF. Whatever their necessity, caspases accelerate the onset of cell death and are responsible for the morphology and correct dismantling of apoptotic cells. Differences observed among myeloma cell lines could be remiscent of differences in apoptotic sensitivity found in myeloma cells from patients. Obviously, further work is needed to precisely characterize the molecular targets of BMS-214662 and how apoptotic signals are generated leading to activation of BH3-only proteins and Mcl-1 degradation. Nevertheless, the FTI BMS-214662 has proved to efficiently induce apoptosis in myeloma cell lines and merits to be evaluated in cells of multiple myeloma patients.

REFERENCES

Adjei AA, JN Davis, LM Bruzek, C Erlichman, and SA Kaufman (2001) Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. *Clin. Cancer Res.* **7:**1438-1445.

Alley MC, DA Scudiero, A Monks, ML Hursey, MJ Czerwinski, DL Fine, BJ Abbott, JG Mayo, RH Shoemaker, and MR Boyd (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. *Cancer Res* **48**(3)**:**589-601.

Bannerman DD, JC Tupper, WA Ricketts, CF Bennett, RK Winn, and JM Harlan (2001) A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis. *J. Biol. Chem.* **276**(18)**:**14924-32.

Beaupre DM, E Cepero, EA Obeng, LH Boise, and MG Lichtenheld (2004) R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. *Mol. Cancer Ther.* **3:**179-186.

Beaupre DM, J McCafferty-Grad, NJ Bahlis, LH Boise, and MG Lichtenheld (2003) Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. *Leuk. Lymph.* **44:**2123-2134.

Bolick SC, TH Landowski, D Boulware, MM Oshiro, J Ohkanda, AD Hamilton, SM Sebti, and WS Dalton (2003) The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. *Leukemia* **17**(2)**:**451-7.

Chen Q, B Gong, and A Almasan (2000) Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. *Cell Death Differ.* **7**(2)**:**227-33.

Chun KH, HY Lee, K Hassan, F Khuri, WK Hong, and R Lotan (2003) Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. *Cancer Res.* **63**(16)**:**4796-800.

Derenne S, B Monia, NM Dean, JK Taylor, MJ Rapp, JL Harousseau, R Bataille, and M Amiot (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. *Blood* **100**(1)**:**194-9.

Du W, PF Lebowitz, and GC Prendergast (1999) Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. *Mol Cell Biol* **19**(3)**:**1831-40.

Gamen S, A Anel, P Lasierra, MA Alava, MJ Martinez-Lorenzo, A Piñeiro, and J Naval (1997) Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. *FEBS Lett.* **417**(3)**:**360-4.

Gamen S, A Anel, A Pineiro, and J Naval (1998) Caspases are the main executioners of Fas-mediated apoptosis, irrespective of the ceramide signalling pathway. *Cell Death and Differentiation* **5**(3)**:**241-9.

Gomez-Bougie P, R Bataille, and M Amiot (2004) The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. *Eur. J. Immunol.* **34**(11)**:**3156-64.

Griffiths GJ, BM Corfe, P Savory, S Leech, M Degli Esposti, JA Hickman, and C Dive (2001) Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the proapoptotic protein Bak. *Oncogene* **20:**7668-7676.

Griffiths GJ, L Dubrez, CP Morgan, NA Jones, J Whitehouse, BM Corfe, C Dive, and JA Hickman (1999) Cell damage-induced conformational changes of the pro-apoptotic protein Bak *in vivo* precede the onset of apoptosis. *J. Cell Biol.* **144:**903-914.

Gross A, XM Yin, K Wang, MC Wei, J Jockel, C Milliman, H Erdjument-Bromage, P Tempst, and SJ Korsmeyer (1999) Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. *Journal of Biological Chemistry* **274**(2)**:**1156-63.

Haluska P, GK Dy, and AA Adjei (2002) Farnesyl transferase inhibitors as anticancer agents. *Eur. J. Cancer* **38**(13)**:**1685-700.

Hu L, Y Shi, JH Hsu, J Gera, B Van Ness, and A Lichtenstein (2003) Downstream effectors of oncogenic ras in multiple myeloma cells. *Blood* **101**(8)**:**3126-35.

Jourdan M, JL Veyrune, JD Vos, N Redal, G Couderc, and B Klein (2003) A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. *Oncogene* **22**(19)**:**2950-9.

Karp JE (2001) Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. *Semin Hematol* **38**(3 Suppl 7)**:**16-23.

Krajewski S, JM Zapata, and JC Reed (1996) Detection of multiple antigens on western blots. *Analytical Biochemistry* **236**(2)**:**221-8.

Kurzrock R, J Cortes, and H Kantarjian (2002) Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. *Semin. Hematol.* **39**(4 Suppl 3)**:**20-4.

Le Gouill S, C Pellat-Deceunynck, JL Harousseau, MJ Rapp, N Robillard, R Bataille, and M Amiot (2002) Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. *Leukemia* **16**(9)**:**1664-7.

Liu Q, S Hilsenbeck, and Y Gazitt (2003) Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. *Blood* **101**(10)**:**4078-87.

Mitsiades CS, N Mitsiades, V Poulaki, R Schlossman, M Akiyama, D Chauhan, T Hideshima, SP Treon, NC Munshi, PG Richardson, and KC Anderson (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. *Oncogene* **21**(37)**:**5673-83.

Nijhawan D, M Fang, E Traer, Q Zhong, W Gao, F Du, and X Wang (2003) Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. *Genes Dev.* **17**(12)**:**1475-86.

Ogata A, D Chauhan, G Teoh, SP Treon, M Urashima, RL Schlossman, and KC Anderson (1997) IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. *J Immunol* **159**(5)**:**2212-21.

Panaretakis T, K Pokrovskaja, MC Shoshan, and D Grander (2002) Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to Doxorubicin. *J. Biol. Chem.* **277**(46)**:**44317-26.

Pei XY, Y Dai, and S Grant (2003) The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. *Leukemia* **17**(10)**:**2036-45.

Perez-Galan P, I Marzo, P Giraldo, D Rubio-Felix, P Lasierra, L Larrad, A Anel, and J Naval (2002) Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia. *Leukemia* **16:**2106-2114.

Piqué M, M Barragán, M Dalmau, B Bellosillo, G Pons, and J Gil (2000) Aspirin induces apoptosis through mitochondrial cytochrome c release. *FEBS Lett.* **480:**193-196.

Reuter CW, MA Morgan, and L Bergmann (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? *Blood* **96**(5)**:**1655-69.

Rose WC, FY Lee, CR Fairchild, M Lynch, T Monticello, RA Kramer, and V Manne (2001)
Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel
farnesyltransferase inhibitor. *Cancer Res.* **61**(20)**:**7507-17.

San Miguel JF, J Blade Creixenti, and R Garcia-Sanz (1999) Treatment of multiple
myeloma. *Haematologica* **84**(1)**:**36-58.

Scoltock AB, and JA Cidlowski (2004) Activation of intrinsic and extrinsic pathways in
apoptotic signaling during UV-C-induced death of Jurkat cells: the role of caspase
inhibition. *Exp. Cell Res.* **297**(1)**:**212-23.

Sebti SM, and AD Hamilton (2000) Design of growth factor antagonists with
antiangiogenic and antitumor properties. *Oncogene* **19**(56)**:**6566-73.

Singh SB, and RB Lingham (2002) Current progress on farnesyl protein transferase
inhibitors. *Curr. Opin. Drug Discov. Devel.* **5**(2)**:**225-44.

Takada Y, FR Khuri, and BB Aggarwal (2004) Protein farnesyltransferase inhibitor (SCH
66336) abolishes NF-kappaB activation induced by various carcinogens and
inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression
and up-regulation of apoptosis. *J. Biol. Chem.* **279**(25)**:**26287-99.

Teoh G, YT Tai, M Urashima, S Shirahama, M Matsuzaki, D Chauhan, SP Treon, N Raje,
T Hideshima, Y Shima, and KC Anderson (2000) CD40 activation mediates p53-
dependent cell cycle regulation in human multiple myeloma cell lines. *Blood*
95(3)**:**1039-46.

Van de Donk NW, MM Kamphuis, B van Kessel, HM Lokhorst, and AC Bloem (2003)
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by
reducing Mcl-1 protein levels. *Blood* **102**(9)**:**3354-62.

Waterhouse NJ, and JA Trapani (2003) A new quantitative assay for cytochrome c
release in apoptotic cells. *Cell Death Differ.* **10**(7)**:**853-5.

Yamaguchi H, SR Paranawithana, MW Lee, Z Huang, KN Bhalla, and H-G Wang (2002)

Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax

conformational change in human breast cancer cells. *Cancer Res.* **62:**466-471.

Zhang B, I Gojo, and RG Fenton (2002) Myeloid cell factor-1 is a critical survival factor

for multiple myeloma. *Blood* **99:**1885-1893.

FIGURE LEGENDS

Figure 1. Effect of BMS-214662 on viability of myeloma cells

(A) Cells (3×10^5 cells/ml) were treated in 96-well plates (100 µl/well) in complete medium with different concentrations of BMS-214662. Cell proliferation was estimated at 24 h by the MTT-□assay. Results are mean of 3-4 individual determinations on two different experiments and are expressed as percentage of cell proliferation relative to controls (without drug). Bars indicate SD. (B) Inhibition of protein farnesylation by BMS-214662. Cells were treated with 1µM (U266), 0.3 µM (RPMI 8226, IM-9) or 75 nM (NCI-H929) of BMS-214662 for 24 h and the mobility of the farnesylated chaperon marker HDJ-2 analyzed by Western blot. BMS-214662 treatment caused the appearance of a slower mobility band corresponding to the unprocessed protein. (C) Induction of nuclear apoptosis by BMS-214662. Cells were treated with the drug for 24 h, stained with PPDA and photographed under epifluorescence illumination. *Arrows*, cells showing chromatin condensation and nuclear fragmentation; *arrowheads*, cells with chromatin condensation. Original magnification, x400.

Figure 2. Caspase activation induced by BMS-214662.

Western blot analysis of the activation of: (A) caspase-9, (B) caspase-3, (C) caspase-8 and (D) caspase-2. Cells were treated for 20 h with 1 µM BMS-214662 (U266), 0.3 µM (RPMI 8226, IM-9) or 75 nM (NCI-H929) and cell extracts analyzed by Western blot with antibodies to caspases 9, 3, 8 and 2. Immunoblots were reprobed with anti-actin or anti-tubulin antibody as a control for equal loading. Activation was characterized by the disappearance of procaspase and, in the case of caspases 2 and 3, by the presence of active subunits.

Figure 3. Effect of peptide caspase inhibitors on BMS-214662-induced apoptosis.

Cells (3×10^5 cells/ml) were incubated for 24 h with BMS-214662 at the indicated doses in the absence or presence of either 100µM Z-VAD-fmk or Z-DEVD-fmk + Z-VEID-fmk+ Z-LEHD-fmk (100 µM each). phosphatidylserine exposure and $\Delta\Psi_m$ were analyzed by annexinV-PE and $DiOC_6(3)$ labeling, respectively. Experiments shown are representative of five different determinations for each cell line.

Figure 4. Effect of BMS-214662 on the levels of Bcl-2 family proteins.

(A) Cells were treated for 20 h with 1 µM BMS-214662 (U266), 0.3 µM (RPMI 8226, IM-9) or 75 nM (NCI-H929) and cell extracts analyzed by Western blot with antibodies to Mcl-1, Bcl-X_L, Bcl-2, Bak, Bad, Bax, Bik and Bim. Immunoblots were reprobed with anti-tubulin as a control for equal loading. (B) Cells were treated for 6 or 18 h with BMS-214662 1 µM (U266), 0.3 µM (RPMI 8226, IM-9) or 75 nM (NCI-H929) and levels of p53 and PUMA analyzed by Western blot. (C) Cells were treated for 20 h with 1 µM BMS-214662 (U266), 0.3 µM (RPMI 8226, IM-9) or 75 nM (NCI-H929) in the absence or in the presence of Z-VAD-fmk and levels of Mcl-1 and PUMA analyzed by Western blot.

Figure 5. BMS-214662 induces proapoptotic conformational changes of Bak and Bax.

U266, RPMI 8226 and NCI-H929 cells were left untreated (A) or incubated for 20 h with 1, 0.3 or 0.075 µM BMS-214662, respectively, in the absence (B) or presence (C) of 100 µM Z-VAD-fmk.   Then, cells were fixed and immunostained with conformation-specific monoclonal anti-Bax (6A7) or anti-Bak (Ab-1) antibodies and analyzed by flow cytometry.

Figure 6. Cytochrome c release induced by BMS-214662.

Cells were left untreated or incubated for 20 h with BMS-216442 at 1µM (U266), 0.3 µM (RPMI 8226, IM-9) or 75 nM (NCI-H929), in the absence or presence of 100 µM Z-VAD-fmk, as indicated. Cells were permeabilized with digitonin, fixed, immunostained with a monoclonal anti-native cytochrome c (6H2.B4) antibody and analyzed by flow cytometry.

Figure 7. Nuclear translocation of AIF.

U266, RPMI 8226 and NCI-H929 cells were left untreated or treated with BMS-214662 in the absence or presence of Z-VAD-fmk, as described.   After 20 h, cells were immunostained with an anti-AIF antibody and analyzed by confocal microscopy. BMS-214662 treated cells show the nuclear localization of AIF, which, except in the case of NCI-H929 cells, is blocked by Z-VAD-fmk.

Figure 1

A

B

**Figure 1**

C

	Control	BMS-214662	BMS-214662 + z-VAD-fmk
U266			
RPMI-8226			
NCI-H929			
IM-9			

Figure 2

Figure 3

U266

CONTROL | BMS-214662 1 μM | BMS-214662 1 μM + Z-VAD-fmk | BMS-214662 1 μM + Z-DEVD-fmk /Z-VEID-fmk/Z-LEHD-fmk

AnnexinV-PE

$DiOC_6(3)$

RPMI-8226

CONTROL | BMS-214662 0.3 μM | BMS-214662 0.3 μM + Z-VAD-fmk | BM-214662 0.3 μM + Z-DEVD-fmk /Z-VEID-fmk/Z-LEHD-fmk

AnnexinV-PE

$DiOC_6(3)$

NCI-H929

CONTROL | BMS-214662 75nM | BMS-214662 75nM + Z-VAD-fmk

Annexin V-PE

$DiOC_6(3)$

IM-9

CONTROL | BMS-214662 0.3μM | BMS-214662 0.3μM + Z-VAD-fmk

Annexin V-PE

$DiOC_6(3)$

Figure 4

A

Figure 4

B

C

Figure 5

U266 · RPMI-8226 · NCI-H929

Bak / Bax columns with rows a, b, c showing percentages.

Figure 6

Cytochrome *c*

Figure 7